Finding – Page 2

After CDC shooting, employees and public health leaders urge RFK Jr. to change his rhetoric

4 weeks ago talkbio0Tagged campus, CDC, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, Leadership, Officer David Rose, public health leaders, RFK Jr. rhetoric, Security Measures, Shooting sensation quality, vaccine misinformation, workplace safety

CDC shooting; RFK Jr. rhetoric; vaccine misinformation; CDC employee reactions; public health leaders; security measures; Atlanta CDC campus; Officer David Rose; HHS leadership; workplace safety

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys

FDA restricts bluebird bio’s Skysona to CALD patients without suitable stem cell donors after higher blood cancer risk emerges

1 month ago talkbio0Tagged boxed, CALD, Cautionary Warning, Cerebral Adrenoleukodystrophy, Donor person, Elivaldogene autotemcel, gene therapy, Hematologic Neoplasms, HLA Match, label update, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, Safety, Skysona, United States Food and Drug Administration

FDA; bluebird bio; Skysona; elivaldogene autotemcel; eli-cel; cerebral adrenoleukodystrophy; CALD; hematologic malignancies; myelodysplastic syndrome (MDS); acute myeloid leukemia (AML); boxed warning; label update; postmarketing safety; HLA-matched donor; gene therapy safety

Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

1 month ago talkbio0Tagged earnings, Eli, Eli Lilly, Expectations, franchise, Glucagon-Like Peptide 1, Obesity, Oral cavity, orforglipron, Q2 2025, regulatory submission, Weight Loss

Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

1 month ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

1 month ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others

1 month ago talkbio0Tagged Administration occupational activities, Amazona, CMS Interoperability Framework, digital health records, Genus Malus, health data, Privacy, tech partnerships, Transplant Registry Unified Management Program

Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships

Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

1 month ago talkbio0Tagged Cardiovascular system, Diabetes Mellitus, Non-Insulin-Dependent, dulaglutide, eli lilly, expansion, Hemoglobin A1c measurement, MACE-3, Mortality Vital Statistics, Mounjaro, non-inferiority, outcomes, SURPASS-CVOT, Trulicity, United States Food and Drug Administration, Weight Loss

Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion

Apellis’ Empaveli Gains FDA Approval for Broad C3 Glomerulopathy Use, Setting Up Competition with Novartis’ Fabhalta

1 month ago talkbio0Tagged Apellis, Approved, C3 glomerulopathy, Empaveli, Fabhalta, Iptacopan, Kidney Diseases, membranoproliferative glomerulonephritis, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Apellis; Empaveli; FDA approval; C3 glomerulopathy; primary immune complex membranoproliferative glomerulonephritis; Novartis; Fabhalta; pegcetacoplan; iptacopan; proteinuria; kidney disease

RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers

1 month ago talkbio0Tagged Advisory Committees, drugmakers, health disparity, HIV Prevention, Insurance, PREP gene, preventive services panel, public health policy, revamp, RFK Jr., USPSTF

RFK Jr.; preventive services panel; USPSTF; PrEP; HIV prevention; insurance coverage; public health policy; drugmakers; health disparities; revamp; task force